Article Figures & Data
- Figure 1
Flowchart of the study. NIHSS, National Institutes of Health Stroke Scale; rt-PA, Recombinant human tissue type plasminogen activator.
- Figure 2
Cumulative probability of primary events. (A) The entire population; (B) population with brief duration (<10 days) of DAPT; (C) population with short duration (10–21 days) of DAPT; (D) population with long duration (>21 days) of DAPT. DAPT, dual antiplatelet therapy; SAPT, single antiplatelet therapy.
- Figure 3
Time course of the absolute treatment difference. DAPT, dual antiplatelet therapy; SAPT, single antiplatelet therapy.
- Figure 4
HR for the primary outcome in subgroups for population with short duration. DAPT, dual antiplatelet therapy; IPTW, inverse probability of treatment weighting; SAPT, single antiplatelet therapy; LAA, large-artery atherosclerosis; TOAST, Trial of Org 10172 in Acute Stroke Treatment; SVO, small-vessel occlusion; OE, stroke of other determined etiology; UD, stroke of undetermined etiology.
- Table 1
Efficacy outcome event rates* of single antiplatelet therapy and dual antiplatelet therapy with aspirin-clopidogrel in patients with short duration
Crude P value† IPTW P value‡ PSM P value§ Number of events/90 days event rate (95% CI), % Number of events/90 days event rate (95% CI), % Number of events/90 days event rate (95% CI), % Primary outcome 0.09 0.03 0.004 SAPT 103/8.9 (7.2~10.5) 125/9.8 (8.1~11.4) 40/11.7 (8.3~15.1) DAPT 64/6.8 (5.2~8.4) 40/6.8 (4.7~8.8) 19/5.6 (3.1~8.0) Secondary outcome Ischaemic stroke 0.08 0.03 0.001 SAPT 88/7.6 (6.0~9.1) 109/8.5 (7.0~10.1) 36/10.5 (7.3~13.8) DAPT 53/5.7 (4.2~7.1) 33/5.6 (3.7~7.4) 14/5.8 (2.8~8.7) TIA 0.89 0.68 0.65 SAPT 8/0.7 (0.2~1.2) 11/0.9 (0.4~1.4) 2/0.6 (-0.2~1.4) DAPT 6/0.6 (0.1~1.2) 4/0.7 (0.0~1.3) 3/0.9 (-0.1~1.9) Safety outcome Severe bleeding 0.43 – – SAPT 3/0.3 (-0.1~0.3) – – DAPT 1/0.1 (-0.1~0.3) – – All ICH 0.00 0.31 0.20 SAPT 30/2.6 (1.7~3.5) 26/2.0 (1.3~2.8) 7/2.0 (0.5~3.6) DAPT 11/1.2 (0.5~1.9) 8/1.4 (0.4~2.3) 3/0.9 (-0.1~1.9) Any bleeding 0.63 0.83 0.77 SAPT 78/6.7 (5.3~8.1) 81/6.3 (5.0~7.7) 25/7.1 (4.5~10.1) DAPT 58/6.2 (4.6~7.7) 36/6.1 (4.2~8.0) 23/6.7 (4.1~9.4) *Event rates were derived from Kaplan-Meier curves.
†P values calculated using log-rank tests.
‡P values calculated using IPTW log-rank tests.
§P values calculated using stratified log-rank tests.
DAPT, dual antiplatelet therapy; IPTW, inverse probability of treatment weighting; PSM, propensity score matching; SAPT, single antiplatelet therapy; s-ICH, symptomatic intracranial haemorrhage; TIA, transient ischaemic attack.
- Table 2
HRs of dual antiplatelet therapy compared single antiplatelet therapy according to the analytical methods used in patients with standard duration
Crude Adjusted* IPTW PSM HR (95% CI) P value† HR (95% CI) P value† HR (95% CI) P value‡ HR (95% CI) P value§ Primary outcome DAPT (vs SAPT) 0.77 (0.56~1.05) 0.09 0.62 (0.41~0.93) 0.02 0.66 (0.46~0.94) 0.02 0.47 (0.27~0.82) 0.008 Secondary outcome Ischaemic stroke DAPT (vs SAPT) 0.74 (0.53~1.04) 0.09 0.57 (0.37~0.88) 0.01 0.64 (0.43~0.94) 0.02 0.39 (0.21~0.72) 0.003 TIA DAPT (vs SAPT) 0.93 (0.32~2.69) 0.89 1.3 (0.21~7.97) 0.77 0.67 (0.2~2.18) 0.50 1.5 (0.25~9.0) 0.66 Safety outcome Severe bleeding DAPT (vs SAPT) 0.62 (0.06~6.84) 0.69 11.61 (0~Inf) 1.00 – – – – All ICH DAPT (vs SAPT) 0.47 (0.23~0.93) 0.03 0.75 (0.28~2.0) 0.56 0.62 (0.28~1.38) 0.24 0.43 (0.11~1.65) 0.22 Any bleeding DAPT (vs SAPT) 0.92 (0.66~1.3) 0.65 0.84 (0.53~1.33) 0.45 1.01 (0.7~1.48) 0.94 0.89 (0.5~1.56) 0.68 *Adjusted for the variables listed in table 1.
†Conventional Cox proportional hazards models.
‡Weighted Cox proportional hazards models.
§Cox proportional hazards models within matched pairs.
DAPT, dual antiplatelet therapy; IPTW, inverse probability of treatment weighting; PSM, propensity score matching; SAPT, single antiplatelet therapy; s-ICH, symptomatic intracranial haemorrhage; TIA, transient ischaemic attack.
Supplementary Materials
Supplementary data
(The content marked red in the article is the revision comments for review, it should be change block color. Thank you very much!)Supplementary data
(The content marked red of sTable 19 and sTable 20 in the article is the revision comments for review, it should be change block color. Thank you very much!)Supplementary data
(The content marked red of sFigure5 in the article is the revision comments for review, it should be change block color. Thank you very much!)Supplementary data
Supplementary data
Additional Files
Supplementary Data
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
